[ Usenet FAQs | Web FAQs | Documents | RFC Index ]
Part1 - Part2 - Part3 - Part4 - Part5 - Single Page
Top Document: diabetes FAQ: treatment (part 3 of 5)
Previous Document: What's the bottom line on pycnogenol?
Next Document: Who did this?
-
Search the FAQ Archives
Part1 - Part2 - Part3 - Part4 - Part5 - Single Page
Top Document: diabetes FAQ: treatment (part 3 of 5)
Previous Document: What's the bottom line on pycnogenol?
Next Document: Who did this?
Pycnogenol references
Written by Laura Clift. This is the section to which the (refs) point. 1. Uchida S, Edamastu R, Hiramatsu M, et al. Condensed tannins scavenge active oxygen free radicals. Med Sci Res 1987;15:831-2. 2.Yu CL, Swaminathan B. Mutagenicity of proanthocyanidins. Food Chem Toxicol 1987;25(2):135-9. 3. Namgoong SY, Son KH, Chang HW, Kang SS, Kim HP. Effects of naturally ocurring flavanoids on mitogen-induced lymphocyte proliferation and mixed lymphocyte culture. Life Sci 1994;54(5):313-20. 4. Cahn J, Borzeix MG. Etude de l'administration des oligomeres du procyanidoliques chez le rat: Effets observes sur les alterations de la permeabilite de la barrier hematoencephalique. La semaine des Hopitaux de Paris 1983;59:2031-4. 5. Lagrue G, Oliver-Martin F, Grillot A. Etude des effects des oliomeres du procyanidol sur la resistance capillaire dans l'hypertension arterielle et certains nephropathies. Las semaine des Hopitaux de Paris 1981; 57:1399-1401. 6. Blazso G, Gabor M. Oedema-inhibiting effect of procyanidin. Acta Physiol Acad Sci Hung 1980;56(2):235-40. 7. Michiels C, Arnould T, Houbion A, Remacle J. A comparative study of the protective effect of different phlebotonic agents on endothelial cells in hypoxia. Phlebologie 1991;44(3):779-86. 8. Lonchampt M, Guardiola B, Sicot N et al. Protective effect of a purified flavanoid fraction against reactive oxygen radicals. in vivo and in vitro study. Arzneimittelforschung 1989;39(8):882-5. 9. Shils ME. Modern nutrition in health and disease. Philadelphia: Lea and Febiger, 1988. p472.
Top Document: diabetes FAQ: treatment (part 3 of 5)
Previous Document: What's the bottom line on pycnogenol?
Next Document: Who did this?
Part1 - Part2 - Part3 - Part4 - Part5 - Single Page
[ Usenet FAQs | Web FAQs | Documents | RFC Index ]
Send corrections/additions to the FAQ Maintainer:
edward@paleo.org
Last Update October 22 2009 @ 05:24 AM